Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 21 EP applications Jernej Kristl has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after January 17, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12723210

BIOMARKERS FOR LUNG CANCER

IPC classification:
C12Q 1/68
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12730099

COMBINATION OF PANOBINOSTAT AND RUXOLITINIB IN THE TREATMENT OF CANCER SUCH AS A MYELOPROLIFERATIVE NEOPLASM

IPC classification:
A61K 31/4045, A61K 31/519
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12766990

PHARMACEUTICAL COMPOSITIONS COMPRISING 40 - O - ( 2 - HYDROXY) ETHYL - RAPAMYCIN

IPC classification:
A61K 9/20, A61K 9/50, A61K 31/436
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP12787709

COMBINATION OF A PHOSPHOINOSITIDE 3-KINASE INHIBITOR AND A MODULATOR OF THE JANUS KINASE 2-SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 5 PATHWAY

IPC classification:
A61K 31/436, A61K 31/437, A61K 31/5377, A61K 45/06, A61P 35/00, A61P 35/04
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
APPLICATION WITHDRAWN
EP14164259

Combination of a rapamycin derivative and letrozole for treating breast cancer

IPC classification:
A61K 31/337, A61K 31/4196, A61K 31/436, A61K 31/502, A61K 31/704, A61K 31/7068, A61K 33/24, A61P 35/00
Applicant:
Novartis AG
Applicant:
Novartis Pharma GmbH
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
The patent has been granted
EP14164565

Treatment of solid brain tumours with a rapamycin derivative

IPC classification:
A61K 31/436, A61P 35/00
Applicant:
Novartis AG
Applicant:
Novartis Pharma GmbH
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
PATENT GRANTED
EP13707527

CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS

IPC classification:
C12Q 1/68
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13721886

BIOMARKERS FOR IAP INHIBITOR THERAPY

IPC classification:
C12Q 1/68
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
PATENT GRANTED
EP14717202

PHARMACEUTICAL COMPOSITIONS COMPRISING EVEROLIMUS

IPC classification:
A61K 9/16, A61K 9/20, A61K 9/28, A61K 31/00
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
PATENT GRANTED
EP14741382

MODIFIED RELEASE FORMULATION

IPC classification:
A61K 9/20, A61K 31/4439
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
PATENT GRANTED
EP12703670

METHODS OF USING ALK INHIBITORS

IPC classification:
A61K 31/00, A61K 31/506, A61P 35/00, C07D 401/12, C07D 401/14
Applicant:
Novartis AG
Agent:
Hoffmann Eitle PartmbB
Agent:
Simon John Kiddle, Mewburn Ellis LLP
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
PATENT GRANTED
EP15188988

COMPOUNDS AND COMPOSITION AS PROTEIN KINASE INHIBITORS

IPC classification:
A61K 31/506, A61P 25/00, A61P 31/00, A61P 37/00, C07D 213/74, C07D 239/48, C07D 239/95, C07D 401/12, C07D 401/14, C07D 403/12, C07D 403/14, C07D 413/12, C07D 417/12, C07D 451/02, C07D 453/02, C07D 471/04, C07D 473/16, C07D 487/04, C07D 487/08
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14732980

ALKYLATION WITH AN ALKYL FLUOROALKYL SULFONATE

IPC classification:
A61K 31/436, C07C 303/28, C07D 498/18
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14766301

COMBINATION OF AN ALK INHIBITOR AND A CDK INHIBITOR FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES

IPC classification:
A61K 31/506, A61K 31/519, A61K 45/00, A61P 35/00
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP16186041

A RAPAMYCIN DERIVATIVE FOR TREATING LUNG CANCER

IPC classification:
A61K 31/436, A61P 35/00
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
Request for examination was made
EP15727470

CERITINIB FORMULATION

IPC classification:
A61K 9/20, A61K 31/435
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15744702

TABLET FORMULATION OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YLMETHYL)IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE

IPC classification:
A61J 3/06, A61J 3/10, A61K 31/4985, A61P 35/00, C07D 487/04
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis AG
Status:
EXAMINATION REQUESTED
EP15824774

COMBINATION THERAPY

IPC classification:
A61K 31/198, A61K 31/4985, A61K 31/505, A61K 31/519, A61P 35/00
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis AG
Status:
EXAMINATION REQUESTED
EP15767682

COMBINATION THERAPIES OF ALK INHIBITORS

IPC classification:
A61K 31/506, A61K 39/395, A61P 35/00, C07K 16/28
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis AG
Status:
Request for examination was made
EP15784975

COMBINATION OF CERITINIB WITH AN EGFR INHIBITOR

IPC classification:
A61K 39/395, A61K 45/06, A61P 35/00
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis AG
Status:
Request for examination was made
EP15883705

CHEMICAL PROCESS FOR PREPARING PYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF

IPC classification:
C07D 211/22, C07D 211/26, C07D 239/26, C07D 401/12
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis AG
Status:
Request for examination was made

Please Sign in to use this feature